Comparing Spectral AI (NASDAQ:MDAI) & Sensus Healthcare (NASDAQ:SRTS)

Sensus Healthcare (NASDAQ:SRTSGet Free Report) and Spectral AI (NASDAQ:MDAIGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Sensus Healthcare and Spectral AI”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sensus Healthcare $27.48 million 1.91 -$7.72 million ($0.47) -6.79
Spectral AI $19.65 million 4.34 -$7.57 million ($0.53) -5.06

Spectral AI has lower revenue, but higher earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sensus Healthcare has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Spectral AI has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sensus Healthcare and Spectral AI, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensus Healthcare 1 1 5 0 2.57
Spectral AI 1 0 1 0 2.00

Sensus Healthcare currently has a consensus price target of $6.88, suggesting a potential upside of 115.52%. Spectral AI has a consensus price target of $3.00, suggesting a potential upside of 11.94%. Given Sensus Healthcare’s stronger consensus rating and higher probable upside, equities analysts plainly believe Sensus Healthcare is more favorable than Spectral AI.

Institutional and Insider Ownership

25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 10.2% of Sensus Healthcare shares are owned by insiders. Comparatively, 13.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sensus Healthcare and Spectral AI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sensus Healthcare -34.50% -15.79% -14.02%
Spectral AI -85.58% N/A -72.97%

Summary

Sensus Healthcare beats Spectral AI on 8 of the 13 factors compared between the two stocks.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

About Spectral AI

(Get Free Report)

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.